|
Status |
Public on Jun 12, 2016 |
Title |
DMSO_Pol2_ChIP |
Sample type |
SRA |
|
|
Source name |
MV4;11_DMSO_ChIP
|
Organism |
Homo sapiens |
Characteristics |
tissue source: peripheral blood cell line: MV4;11 cell type: Mixed lineage leukemia (MLL) fusion protein (FP) leukemia cell line treatment: 0.1% DMSO chip antibody: anti-RNA Pol II (CTD4H8, Millipore, lot 2491218)
|
Treatment protocol |
Cell lines were grown in 0.1% DMSO, 500nM of I-BET151 and/or 5uM of SGC0946
|
Growth protocol |
Cell lines were grown in RPMI-1640 supplemented with 20% fetal calf serum, penicillin (100 units/mL) and streptomycin (100 ug/mL)
|
Extracted molecule |
genomic DNA |
Extraction protocol |
Lysate were isolated from formaldehybe cross-linked cells and sonicated to release the chromatin, then immunoprecipitated with antibody ThruPLEXTM-FD Prep Kit protocol (Rubicon Genomics)
|
|
|
Library strategy |
ChIP-Seq |
Library source |
genomic |
Library selection |
ChIP |
Instrument model |
Illumina HiSeq 2000 |
|
|
Data processing |
Illumina Casava1.8.2 software was used for basecalling. Reads were aligned to the human genome (G1k V37) using bwa 0.6.2-r126 Peak-calling was performed using MACS2 Genome_build: hg19 Supplementary_files_format_and_content: bed files from MACS2 for each sample
|
|
|
Submission date |
Aug 06, 2015 |
Last update date |
May 15, 2019 |
Contact name |
Mark Dawson |
E-mail(s) |
mark.dawson@petermac.org
|
Organization name |
Peter MacCallum Cancer Centre
|
Street address |
305 Grattan Street
|
City |
Melbourne |
State/province |
VIC |
ZIP/Postal code |
3000 |
Country |
Australia |
|
|
Platform ID |
GPL11154 |
Series (2) |
GSE71776 |
ChIPSeq of MV4;11 cell treated with DMSO, I-BET, SGC0946 and combination of I-BET and SGC0946 |
GSE71780 |
Functional interdependency of BRD4 and DOT1L in MLL leukaemia |
|
Relations |
SRA |
SRX1134742 |
BioSample |
SAMN03979578 |